VERASTEM INC (VSTM)       0.4382  +0 (+0.64%)

0.4382  +0 (+0.64%)

US92337C1045 - Common Stock - After market: 0.41 -0.03 (-6.44%)


Fundamental Rating

3

Overall VSTM gets a fundamental rating of 3 out of 10. We evaluated VSTM against 632 industry peers in the Biotechnology industry. VSTM has a bad profitability rating. Also its financial health evaluation is rather negative. VSTM is quite expensive at the moment. It does show a decent growth rate.




Profitability

Profitability Rating

1

The profitability ratios for VSTM are negative, so there is not much use analyzing them.
VSTM has a Return On Assets of -66.15%. This is below the industry average of -44.83%.

VSTM's Profit Margin of -2339.54% is worse than the rest of the industry. The industry average Profit Margin is -444.43%.
VSTM has a quite weak Piotroski-F score of 3.00. This indicates issues in the health and profitability of VSTM.
VS Industry

ROA (-66.15%) VS Industry: 30% outperformed.

-950.38
52.28

Profit Margin (-2339.54%) VS Industry: 23% outperformed.

-1,173,705.71
34,743.00

Valuation

Valuation Rating

2

Compared to an average Enterprise Value to EBITDA ratio of 1.07, VSTM is valued rather cheaply. On top of this, VSTM has a better ratio than 81% of the companies listed in the same industry.
With a price book ratio of 1.46, VSTM is valued correctly.
When comparing the price book ratio of VSTM to the average industry price book ratio of 1.72, VSTM is valued in line with its industry peers.

VSTM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VSTM. No positive earnings are expected for the next year.
VS Industry

Price/Book (1.46) VS Industry: 56% outperformed.

137.61
0.10

Enterprise Value/ EBITDA (0.27) VS Industry: 81% outperformed.

3,469.94
0.01

Growth

Growth Rating

6

VSTM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.36%, which is quite good.
The Revenue has grown by 55.34% in the past year. This is a very strong growth!
VSTM is expected to show a strong growth in Revenue. In the coming 5 years, the Revenue will grow by 146.36% yearly.

When comparing the Revenue growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
Based on estimates for the next 5 years, VSTM will show a decrease in Earnings Per Share. The EPS will decrease by -0.77% on average per year.
The Revenue for VSTM have been decreasing by -57.49% on average. This is quite bad

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 11.36% -8.22% 3.9% 3.52% -0.77%
RevenueN/A -57.49% 55.34% 201.94% 293.57% 168.06% 146.36%

Health

Health Rating

3

A Current Ratio of 4.97 indicates that VSTM has no problem at all paying its short term obligations.
VSTM has a Quick Ratio of 4.97. This indicates that VSTM is financially healthy and has no problem in meeting its short term obligations.
The Current Ratio is in line with the industry averages, which is at 6.16.
VSTM has a Quick Ratio comparable to the industry average, which is at 6.05.

Compared to an average industry Debt to Equity Ratio of 0.00, VSTM is requires more financing than its industry peers. 87% of its industry peers have a better Debt to Equity Ratio.
Based on the Altman-Z score of -9.21, we must say that VSTM is in the distress zone and has some risk of bankruptcy.
When comparing the Altman-Z score of VSTM to the average industry Altman-Z score of -0.81, VSTM is less financially healthy than its industry peers. 82% of its industry peers have a better Altman-Z score.
The Piotroski-F score of VSTM is 3.00. This is a low score and indicates issues in the health and profitability of VSTM.
VS Industry

Debt/Equity (0.39) VS Industry: 13% outperformed.

15.37
0.00

Quick Ratio (4.97) VS Industry: 42% outperformed.

0.02
84.53

Current Ratio (4.97) VS Industry: 41% outperformed.

0.02
85.09

Altman-Z (-9.21) VS Industry: 18% outperformed.

-135.10
443.02

Dividend

Dividend Rating

0

VSTM does not give a dividend.

VSTM Daily chart

VERASTEM INC0.4382

NASDAQ:VSTM (12/2/2022, 7:09:16 PM)+0 (+0.64%)

After market: 0.41 -0.03 (-6.44%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-03 2022-11-03/amc Earnings (Next) 03-27 2023-03-27
Ins Owners 1.58% Inst Owners 52.46%
Market Cap 92.06M Analysts 83.33
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S 29.31 P/B 1.46
EV/EBITDA 0.27
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A
Growth
EPS 1Y 11.36% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 30.77%
EPS Next Y -8.22% EPS Next 2Y 3.9%
EPS Next 3Y 3.52% EPS Next 5Y -0.77%
Revenue growth 1Y 55.34% Revenue growth 3Y -57.49%
Revenue growth 5Y N/A Revenue growth Q2Q -100%
Revenue Next Year 201.94% Revenue Next 2Y 293.57%
Revenue Next 3Y 168.06% Revenue Next 5Y 146.36%
Health
Current Ratio 4.97 Quick Ratio 4.97
Altman-Z -9.21 F-Score 3
Debt/Equity 0.39 WACC 9.64%
ROIC/WACC N/A
Profitability
ROA -66.15% ROE N/A
ROICexgc N/A ROIC N/A
PM -2339.54% OM -2311.43%
Asset Turnover 0.03

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA